Atlas Trials

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Clinical trial NCT05956639 · RECRUITING

Trial details

NCT number
NCT05956639
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Start date
2023-06-20
Primary completion
2025-12-31
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.